48 reports

  • Stages of bladder cancer
  • Identifying factors that impede market growth

About Bladder Cancer Therapeutics The bladder is an organ located in the lower abdominal region near the pelvic bones and acts as a reservoir of urine. A bladder cancer is characterized by the abnormal cell growth in the bladder, which impairs the proper functioning of urinary system. Majority of bladder cancer develops in the...

  • Bladder Cancer
  • Cancer
  • Therapy
  • Bristol-Myers Squibb Company
  • Eli Lilly & Co.
  • 11.1 BIBLIOGRAPHY
  • AVAILABLE

GENES CANCER; ##(##): ##- ##.

  • Cancer
  • Colorectal Cancer
  • Hospital
  • Therapy
  • Eli Lilly & Co.
  • COSTS OF FEW LUNG CANCER DRUGS ($)
  • MARKET PENETRATION OF VARIOUS LUNG CANCER THERAPEUTICS MANUFACTURERS IN GLOBAL (2015)

About Lung Cancer Therapeutics Lung cancer is a common cause of mortality and morbidity in both developed and developing countries. Smoking is a major cause of lung cancer, though it also occurs in non-smokers. Lung cancer can be categorized into two major types, namely NSCLC and SCLC. NSCLC is the commonest type of lung cancer and constitutes...

  • Cancer
  • Lung Cancer
  • Therapy
  • AstraZeneca PLC
  • Eli Lilly & Co.
  • Cancer Supportive Care Market, Global, Revenue for Tanezumab (Eli Lilly/Pfizer)
  • Cancer Supportive Care Market, Global, Companies by Compound Annual Growth

Global Cancer Supportive Care Therapeutics Market to 2022 - Patent Expirations Create Opportunities for Biosimilars in the Chemotherapy Induced Anemia and Neutropenia Markets Summary Cancer is a disease characterized by abnormal cell growth and uncontrolled proliferation caused by a series of mutations that result in the...

  • Blood Disease
  • Cancer
  • Therapy
  • Amgen Inc.
  • Eli Lilly & Co.
  • EARLY-STAGE CLINICAL DEVELOPMENT IN NSCLC
  • CLINICAL AND COMMERCIAL POSITIONING OF FRUQUINTINIB

INTERNATIONAL JOURNAL OF CANCER; ##(##): ##-##.

  • Cancer
  • Hospital
  • Lung Cancer
  • Therapy
  • Eli Lilly & Co.
  • 9.1.4 PHASE I
  • Pipeline Analysis

BMC Cancer; ##(##); ##-## Lubin JH, et al. (2004).

  • Cancer
  • Lung Cancer
  • Targeted Therapy
  • Therapy
  • Eli Lilly & Co.
  • SUMMARIZES INNOVATIVE EARLY STAGE APPROACHES FOR PANCREATIC CANCER.
  • 6.9 GEMCITABINE

Pancreatic Cancer: Opportunity Analysis and Forecast to 2026 Summary Pancreatic cancer is set to become the second leading cause of cancer-related deaths in the US in 2020 after lung cancer, despite accounting for only 3% of new cancer diagnoses. Patients with advanced pancreatic cancer have a median...

  • Cancer
  • Pancreatic Cancer
  • United States
  • Forecast
  • Eli Lilly & Co.
  • Non-hematological Cancer, Global, Key Marketed Products and Approved Indications, 2015
  • Pipeline Landscape Assessment

Global Non-Hematological Cancers Market to 2021 - Strong growth driven by increased uptake of low toxicity targeted treatments and versatile biologics Summary In 2012, there were 32.6 million people living with any type of cancer within five years of diagnosis, non-hematological cancers are thought to account for 94% of...

  • Cancer
  • Clinical Trial
  • Oncology
  • Therapy
  • Eli Lilly & Co.
  • Eli Lilly
  • Vendor landscape

PART ##: Disease overview TYPES OF GASTRIC CANCER Gastric cancer is one of the common types of cancer.

  • Cancer
  • Gastric Cancer
  • Therapy
  • Eli Lilly & Co.
  • F. Hoffmann-La Roche Ltd.

Colorectal Cancer: Competitive Landscape to 2026 Report Code: GDHC##CL Published: April 2018 Healthcare TABLE OF CONTENTS ##.

  • Cancer
  • Clinical Trial
  • Colorectal Cancer
  • Array BioPharma Inc.
  • Eli Lilly & Co.
  • EXPECTED KEY UPDATES TO THE BLADDER CANCER COMPETITIVE LANDSCAPE
  • KOL INSIGHT ON THE UPDATES TO THE BLADDER CANCER COMPETITIVE LANDSCAPE (APRIL 2017-FEBRUARY 2018)

Bladder Cancer: Dynamic Market Forecast to 2026 Summary Bladder cancer is a rapidly evolving field in which new developments are constantly influencing the market landscape. The Dynamic Market Forecast is designed to help clients stay abreast of the latest news in the bladder cancer space, including...

  • Cancer
  • Vaccine
  • Market Size
  • Eli Lilly & Co.
  • Merck & Co., Inc.

Gastric cancer

4546 5000 3864
  • Marketed Drugs: Gastric Cancer
  • Pipeline: Gastric Cancer

Pipeline therapies will look to fulfil many areas of high unmet need left by the lack of targeted therapies approved for the treatment of gastric cancer. This report addresses the following questions: - What impact will the PD-1/PD-L1 inhibitor class of drugs have on the gastric cancer market? - How will pipeline immunotherapies...

  • Cancer
  • Chemotherapy
  • Gastric Cancer
  • Therapy
  • Eli Lilly & Co.

Head and neck cancer

4546 5000 3864

Nature Reviews Cancer, ##(##), ##-## < DOI> ##. ##/ nrc##< / DOI>.

  • Cancer
  • European Union
  • Japan
  • United States
  • Eli Lilly & Co.
  • 7.8 ELI LILLY- PRODUCT PORTFOLIO
  • 7.8 ELI LILLY- COMPANY OVERVIEW

One of the major causes of cancer in Japan is smoking.

  • Cancer
  • Chemotherapy
  • Therapy
  • Amgen Inc.
  • Eli Lilly & Co.

Colorectal cancer

4546 5000 3864
  • Forecast: Colorectal Cancer
  • Marketed Drugs: Colorectal Cancer

Pipeline candidates for the colorectal cancer market will pursue novel mechanisms of action to distinguish themselves in an increasingly crowded market. This report addresses the following questions: - How are new therapies differentiating themselves in the increasingly crowded and price-sensitive CRC market? - How...

  • Cancer
  • Chemotherapy
  • Colorectal Cancer
  • Therapy
  • Eli Lilly & Co.

Pancreatic cancer

4546 5000 3864
  • Marketed Drugs: Pancreatic Cancer
  • Pipeline: Pancreatic Cancer

The prognosis of patients with pancreatic cancer remains poor; however, this clinical need will drive future market expansion and the development of several targeted therapies. This report addresses the following questions: -What are the current treatment options for patients with pancreatic cancer in each therapeutic...

  • Cancer
  • Obesity
  • Pancreatic Cancer
  • Therapy
  • Eli Lilly & Co.
  • Pipeline: Hepatocellular Cancer
  • Clinical development of Cyramza in hepatocellular cancer

The success of Nexavar has boosted the development of new targeted therapies, approvals of which will drive the growth of the hepatocellular cancer market. This report addresses the following questions: - Which products will drive the growth of the hepatocellular cancer market? - What is the commercial potential for...

  • Cancer
  • Healthcare
  • Hepatitis
  • Therapy
  • Eli Lilly & Co.
  • 8.1 REFERENCES

Cancer Discovery; ##(##): ##-## Hanahan D and Weinberg RA (2011).

  • Cancer
  • Cancer Immunotherapy
  • Lung Cancer
  • Therapy
  • Eli Lilly & Co.

Late diagnosis of the disease is one of the major problems for cancer.

  • Cancer
  • Ear, Nose, And Throat Medicine
  • Market Size
  • Bristol-Myers Squibb Company
  • Eli Lilly & Co.
  • GLOBAL SALES ($M) OF BRANDED PRODUCTS FOR HER2-NEGATIVE BREAST CANCER BY COMPANY*,
  • PROVIDES A SWOT ANALYSIS OF ELI LILLY.

PharmaPoint: HER2-Negative Breast Cancer - Global Drug Forecast and Market Analysis to 2023 Summary Breast cancer is the second most common cancer in the world and the most common cancer in women worldwide. This report focuses on the current treatment landscape, unmet needs, current pipeline, and commercial opportunities...

  • Cancer
  • World
  • Demand
  • Market Size
  • Eli Lilly & Co.
  • Pipeline portfolio
  • MERCK

About Cancer Immunotherapies Cancer immunotherapy works by enhancing the innate powers of the immune system. This has better chances of successfully fighting cancer for a long period. Also, immunotherapies have fewer side effects and can treat different types of cancer. Cancer immunotherapies make up nearly 50% of the cancer drugs...

  • Cancer
  • Cancer Immunotherapy
  • Therapy
  • Market Size
  • Eli Lilly & Co.
  • CLINICAL TRIAL DESIGN OF KEY PIPELINE DRUGS IN THE MIBC AND METASTATIC SETTINGS
  • KEYTRUDA SWOT ANALYSIS

NATURE REVIEWS CANCER; ##(##): ##-##.

  • Bladder Cancer
  • Cancer
  • Hospital
  • Therapy
  • Eli Lilly & Co.
  • T-Cell Redirecting Bispecific Cancer Antibodies - 4/30
  • ZYMEWORKS - 4/4

Competitor Analysis: Bispecific Antibodies for Cancer, Inflammatory &amp; Other DiseasesThis Competitive Intelligence report about Bispecific Antibodies for Cancer, Inflammatory &amp; Other Diseases evaluates the competitive landscape of bispecific therapeutic antibodies for treatment of cancer, anti-inflammatory...

  • Biological Therapy
  • Cancer
  • Monoclonal Antibody
  • Affimed Therapeutics AG
  • Eli Lilly & Co.
  • CHAPTER III CERVICAL CANCER TREATMENT DRUGS INDUSTRY ASSESSMENTS
  • Overview

The Cervical Cancer Chapter V CERVICAL CANCER TREATMENT DRUGS MARKET OUTLOOK Treatment Drugs industry is one of the pillar industries in China.

  • Cancer
  • Cervical Cancer
  • Pharmaceutical
  • Eli Lilly & Co.
  • Hubei HONCH Pharmaceutical Co., Ltd.
  • CHAPTER IV BREAST CANCER TREATMENT DRUGS PRODUCTION AND DEMAND
  • Breast Cancer Treatment Drugs Sales Volume

Overview CHAPTER IV BREAST CANCER TREATMENT DRUGS PRODUCTION AND DEMAND The Breast Cancer is one of the most frequent cancers happened on woman body, around the world, there are ##. ## million women tortured by this disease and ##. ## million of them was died every year.

  • Breast Cancer
  • Cancer
  • Hormone
  • Therapy
  • Eli Lilly & Co.
  • 201 FOR PROSTATE CANCER
  • CO-DEVELOPMENT AGREEMENT FOR CANCER THERAPEUTICS

The Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2012-2018 report provides comprehensive understanding and unprecedented access to the co-development deals and agreements entered into by the worlds leading life science companies. This report provides details of the latest...

  • Cancer
  • Pharmaceutical
  • AbbVie Inc.
  • Amgen Inc.
  • Eli Lilly & Co.
  • EARLY-STAGE MET-TARGETING DRUGS

BRITISH JOURNAL OF CANCER; ##(##): ##-##.

  • Cancer
  • Chemotherapy
  • Gastric Cancer
  • Therapy
  • Eli Lilly & Co.
  • 8. Global Renal Cell Carcinoma Drugs Market - Company Wise Pipeline Analysis
  • dalantercept (Acceleron)

Renal cell carcinoma is the most common type of kidney cancer in adults. It accounts for approximately 3% of adult malignancies and 90-95% of neoplasms arising from the kidney. The global renal cell carcinoma drugs market is anticipated to cross US$ 4.3 Billion mark by 2021. There are many factors, like smoking, hypertension, unhealthy eating...

  • Cancer
  • Renal Cancer
  • Targeted Therapy
  • Eli Lilly & Co.
  • Exelixis, Inc.
  • CHAPTER III CERVICAL CANCER TREATMENT DRUGS INDUSTRY ASSESSMENTS

It can control the spread of cancer cells, and extend the life time of patients who are ill with cervical cancer.

  • Cancer
  • Cervical Cancer
  • Pharmaceutical
  • Eli Lilly & Co.
  • Hubei HONCH Pharmaceutical Co., Ltd.

Estrogen signaling is involved in a number of diseases with big market indications such as breast cancer, prostate cancer and osteoporosis.

  • Breast Cancer
  • Cancer
  • Hormone
  • Therapy
  • Eli Lilly & Co.